Last reviewed · How we verify

bOPV and IPV

Aga Khan University · FDA-approved active Biologic ✓ Verified May 2026 Quality 2/100

bOPV and IPV is a Biologic drug developed by Aga Khan University. It is currently FDA-approved.

bOPV and IPV are types of vaccines used to prevent polio and other diseases such as diphtheria, tetanus, and pertussis, as well as measles, mumps, and rubella. They are administered through a vaccination schedule that may include sIPV and wIPV, and are classified as small molecule interventions.

At a glance

Generic namebOPV and IPV
SponsorAga Khan University
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bOPV and IPV

What is bOPV and IPV?

bOPV and IPV is a Biologic drug developed by Aga Khan University.

Who makes bOPV and IPV?

bOPV and IPV is developed and marketed by Aga Khan University (see full Aga Khan University pipeline at /company/aga-khan-university).

What development phase is bOPV and IPV in?

bOPV and IPV is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing